MedTrace Logo

Guanfacine to Treat Borderline Personality Disorder

NCT00358969 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2006-08-01

No results posted yet for this study

Summary

This study is designed to investigate whether guanfacine (Tenex) is an effective treatment for borderline personality disorder (BPD), an illness often characterized by unstable mood and impulsive aggression. Guanfacine stimulates activity in the front portion of the brain, a region associated with attention and the control of behavior. We believe that guanfacine may improve symptoms of BPD by improving attention and aiding regulation of behavior.

Conditions

  • Borderline Personality Disorder

Interventions

DRUG

guanfacine (Tenex)

Sponsors & Collaborators

Principal Investigators

  • Antonia S. New, M.D. · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00358969 on ClinicalTrials.gov